Press releases

Stockholm – September 4, 2023 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that two new articles with scientific data on melflufen, marketed in Europe as Pepaxti, has been published in Haematologica, a publication reporting on important findings in basic, clinical and translational research within hematology. The published data from two studies, ANCHOR and LIGHTHOUSE, provides additional scientific support for the clinical benefit of melflufen and dexamethasone in combination with daratumumab or bortezomib in relapsed refractory multiple myeloma (RRMM)

Stockholm – August 25, 2023 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that more information regarding the formal request from the U.S. Food and Drug Administration (FDA) to voluntarily withdraw Pepaxto´s approval in the U.S has been made available by the FDA

Stockholm – August 10, 2023 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today publishes the report for the second quarter 2023

Stockholm – August 9, 2023 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the Company has appointed Henrik Bergentoft as Chief Financial Officer, CFO. Henrik was most recently CFO at RaySearch Laboratories and brings 20+ years of experience from leading finance roles at both medical and non-medical, publicly listed organizations. He will assume his new position during the fourth quarter, replacing Holger Lembrér

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announced that CEO Monica Shaw will be departing the company and transition over to Sofia Heigis who will move from the CCO role to take on the CEO role

STOCKHOLM – August 3 2023 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, will publish the report for the first quarter 2023 at 08:00 CET on August 10. Investors, financial analysts, and media are invited to participate in a webcast and a following Q&A session on August 10 at 09:00 CET

STOCKHOLM — July 31, 2023 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the number of shares and votes in Oncopeptides has changed as a result of the company’s issue of 219,843 new class C shares in accordance with the shareholder program Board SHP 2023 adopted by the annual general meeting on May 25, 2023

STOCKHOLM — June 28, 2023 — The Board of Directors of Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) (“Oncopeptides”), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, has today resolved, by virtue of the authorisation by the Annual General Meeting held on 25 May 2023, to issue and immediately thereafter re-purchase a total of 219 843 class C shares. The shares are issued and re-purchased in accordance with the shareholder program which was adopted by the Annual General Meeting held on 25 May 2023 (“Board SHP 2023”)

STOCKHOLM – June 19, 2023 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announced its first named patient sales of its flagship drug Pepaxti in Greece. The sales were made possible through Oncopeptides’ partnership with Ariti S.A., a company specialized on medical and pharmaceutical supply in Greece

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announced that Holger Lembrér, Chief Financial Officer (CFO) has decided to leave Oncopeptides to pursue a new role in another company. Holger was appointed CFO in January 2023. He will continue in his current role until December or until a new CFO takes office. A recruitment process will be initiated immediately